Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome

Bibliography

• Carter AB, May MM, Perry WJ. The day after: action following a nuclear blast in a U.S. city. Washington Quarterly 2007;30:19-32
   Web of Science ®Google Scholar
• Singh VK, Newman VL, Romaine PL, et al. Radiation countermeasure agents: an update (2011 - 2014). Expert Opin Ther Pat 2014;24:1229-55
   PubMed Web of Science ®Google Scholar
• Singh VK, Romaine PL, Newman VL. Biologics as countermeasures for acute radiation syndrome: where are we now? Expert Opin Biol Ther 2015;15:465-71
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves Neupogen® for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. 2015. Available from: http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm443245.htm [Last accessed 17 April 2015]
   Google Scholar
• Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine 2015;71:22-37
   PubMed Web of Science ®Google Scholar
• Gridley DS, Pecaut MJ, Dutta-Roy R, Nelson GA. Dose and dose rate effects of whole-body proton irradiation on leukocyte populations and lymphoid organs: part I. Immunol Lett 2002;80:55-66
   PubMed Web of Science ®Google Scholar
• Pecaut MJ, Gridley DS, Smith AL, Nelson GA. Dose and dose rate effects of whole-body proton-irradiation on lymphocyte blastogenesis and hematological variables: part II. Immunol Lett 2002;80:67-73
   PubMed Web of Science ®Google Scholar
• Singh VK, Newman VL, Berg AN, MacVittie TJ. Animal models for acute radiation syndrome drug discovery. Expert Opin Drug Discov 2015;10:497-517
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. Radiobiology for the Radiobiologist. 7th edition. Lippincott Williams and Wilkins; Philadelphia, PA; 2012
   Google Scholar
• Lataillade JJ, Doucet C, Bey E, et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen Med 2007;2:785-94
   PubMed Web of Science ®Google Scholar
• Muller K, Meineke V. Radiation-induced alterations in cytokine production by skin cells. Exp Hematol 2007;35:96-104
   PubMed Web of Science ®Google Scholar
• Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immun 2002;3:221-7
   Google Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103
   PubMed Web of Science ®Google Scholar
• Gudkov A. Modulating apoptosis. US7638485B2, US8106005, US8784840, US20060275255, US20100056454, US20100120687, US20150072931; 2009
   Google Scholar
• Gudkov A. Method for reducing the effects of chemotheraphy using flagellin related polypeptides. WO2009102818. US8580321, US20090246303, US20130324462; 2009
   Google Scholar
• Gudkov A, DiDonato J, Krivolkrysenko V. Flagellin related polypeptides and uses thereof. EP01838340A1, EP02460534A1, IL184140D0, IL227910D0, JP2008525472A, JP5285278B2, US08007812B2, US08287882B2, US08932609B2, US20090011982A1, US20110319344A1, US20110319595A1, US20140294900A1, WO2006069198A1; 2014
   Google Scholar
• Gudkov A. Methods of protecting against radiation using flagellin. CA2547869A1, CA2547869C, CN1913915A, CN1913915B, DE602004029500D1, EP1706133A2, EP1706133B1, WO2005056042A3, WO2005056055A2, WO2005056055A3, WO2005057218A2, WO2005057218A3; 2005
   Google Scholar
• Gudkov A, Burdelya L. Compositions and methods comprising Toll-like receptor (TLR) stimulating agents for prophylaxis and therapy for damage to dermal epithelium. WO2013151994, EP2833876A1; 2013
   Google Scholar
• Mogelsvang S, Gelber C. Peptides and methods of using same. US20140378372A1, CA2859777A1, EP2802338A2, US8975224, US20130274187, WO2013106273A2, WO2013106273A3; 2014
   Google Scholar
• Mogelsvang S, Gelber C. Peptides and methods of using same. WO 2013106273 A2 20130718, WO 2013106273 A3 20131219, AU 2013208293 A1 20140626, CA 2859777 A1 20130718, EP 2802338 A2, 20141119, IL 233481 D0 20140831, JP 2015504073 A 20150205, MX 2014007799 A 20141024, US 2013274187 A1 20131017, US 2014378372. A1 20141225, US 2015133375 A1 20150514, US 8975224 B2 20150310; 2015
   Google Scholar
• Shakhov A, Strom E. Methods for increasing and mobilizaing hematopoietic stem cells. WO 2008086426 A2 20080717, WO 2008086426 A3 20081218, WO 2008086426 A8 20090730, AU 2008204836 A1 20080717, BR PI0806557, A2 20140415, CA 2675032 A1 20080717, CN 101631850 A 20100120, CN 101631850 B 20131204, EA 018983 B1 20131230, EA 200900806, A1 20100830, EP 2115124 A2 20091111, EP 2115124 A4 20120530, HK 1134835 A1 20140808, IL 199766 A 20150129, JP 2010515748 A, 20100513, JP 5389666 B2 20140115, KR 101493474 B1 20150216, KR 20090108703 A 20091016, MX 2009007391 A 20090813, NZ 578928 A, 20130328, NZ 603805 A 20140328, SG 177959 A1 20120228, US 2010055077 A1 20100304, US 2014045747 A1 20140213, ZA 200905378 A 20100526; 2012
   Google Scholar
• Shakhov A, Strom E. Methods for increasing and mobilizing hematopoietic stem cells. CA2675032A1, CN101631850A, CN101631850B, EP2115124A2, EP2115124A4, US20100055077, WO2008086426A2, WO2008086426A3, WO2008086426A8; 2014
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. US8008260B2, CA2612102A1, CN101242852A, CN101242852B, EP1904084A2, EP1904084A4, EP1904084B1, EP2554181A2, EP2554181A3, EP2554181B1, US8524668, US9006183, US20090214467, US20110237507, US20140045750, WO2006138238A2, WO2006138238A3; 2011b
   Google Scholar
• Shakhov A, Gudkov A. Methods of protecting against apoptosis using lipopeptides. AU2006259630A1, AU2006259630B2, BRPI0611586A2, CA2612102A1, CN101242852A, CN101242852B, EA014644B1, EA200702510A1, EP01904084A2, EP01904084B1, EP02554181A2, EP02554181B1, ES2421447T3, HK1123495A1, IL188091A, IL188091D0, JP2008543847A, JP5000644B2, KR20080030566A, KR20140041874A, MX2007015834A, NZ565063A, PT1904084E, US08524668B2, US09006183B2, US20090214467A1, US20110237507A1, US20140045750A1, WO2006138238A2, ZA200800126A; 2011a
   Google Scholar
• Gleiberman A, Burdelya L, Gudkov A. Use of Toll-like receptor agonist for treating cancer. EP2663367A4, CA2824438A1, CN103476458A, EP2663367A1, US20140248260, WO2012097012A1; 2014
   Google Scholar
• Gleiberman A, Burdelya L, Gudkov A. Use of toll-like receptor agonist for treating cancer. WO 2012097012 A1 20120719, AU 2012205681 A1 20130718, CA 2824438 A1 20120719,CL 2013002001 A1 20140328, CN 103476458 A 20131225, CO 6781506 A2 20131031, EA 201390843 A1 20131230, EP 2663367 A1 20131120, EP 2663367 A4 20140806, IL 227308 D0 20130930, JP 2014502973 A 20140206, KR 20140030132 A 20140311, MX 2013007967 A 20130821, SG 191830 A1 20130830, US 2014248260 A1 20140904; 2014
   Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30
   PubMed Web of Science ®Google Scholar
• Krivokrysenko VI, Shakhov AN, Singh VK, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther 2012;343:497-508
   PubMed Web of Science ®Google Scholar
• Singh VK, Ducey EJ, Fatanmi OO, et al. CBLB613: A TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat Res 2012;177:628-42
   PubMed Web of Science ®Google Scholar
• Shakhov AN, Singh VK, Bone F, et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS One 2012;7:e33044
   PubMed Web of Science ®Google Scholar
• Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl) 2009;87:125-38
   PubMed Web of Science ®Google Scholar
• Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004;140:1037-51
   PubMed Web of Science ®Google Scholar
• Gourmelon P, Benderitter M, Bertho JM, et al. European consensus on the medical management of acute radiation syndrome and analysis of the radiation accidents in Belgium and Senegal. Health Phys 2010;98:825-32
   PubMed Web of Science ®Google Scholar